Researchers from MIT and Dana-Farber Cancer Institute have discovered that a class of peptides expressed in pancreatic cancer ...

Patients older than 65 years had similar clinical outcomes in response to immune checkpoint inhibitors as younger patients with cancer.

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical ...

Immunotherapy uses a person's own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy ...

NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

Immunotherapy treatments such as checkpoint blockade inhibitors, which are designed to help stimulate the body's own T cells to attack tumor cells, are usually not effective against pancreatic tumors.

Ipilimumab, a cancer immunotherapy, reduced scar formation and promoted tissue regeneration in a mouse model of idiopathic ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...